Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing...( -Second Data Set Presented at MDS- .....),Health

-Second Data Set Presented at MDS-

PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future.

The NT-201 data presented at the Movement Disorder Society's annual meeting includes the following three abstracts: Efficacy and safety of NT-201 (Xeomin(R); botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients, Efficacy and safety of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients, and Repeated injections of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in upper limb spasticity patients.

Eric Pappert, M.D., Vice President of Medical Affairs, Merz Pharmaceuticals, USA said, "These findings suggest Xeomin, the brand name for NT-201 in Europe, may be a new option in the treatment of movement disorders in the United States."

First Study -Title

Efficacy and safety of NT-201 (Xeomin(R), botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients authored by Susanne Grafe, Cynthia Comella, Joseph Jankovic, Daniel Truong, and Angelika Hanschman.

Method

CD patients previously treated with another brand of BoNTA were randomized to placebo, 120 U NT 201, or 240 U NT-201. Following injection, patients were evaluated at 4 weeks using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Adverse events (AEs) were also collected up
'/>"/>